Drug ID:Drug53
Drug Name:Ferrous sulphate
CID:24393
DrugBank ID:DB13257
Modality:Small Molecule
Groups:NULL
US Approved:NO
Other Approved:YES
Identifier: NCT01991314, , NCT02774057, , NCT01536535
Molecular Formula:FeO4S
Molecular Weight:151.91 g/mol
Isomeric SMILES:[O-]S(=O)(=O)[O-].[Fe+2]
Synonyms:FERROUS SULFATE; Iron sulfate; Ferrous sulfate anhydrous; Iron sulphate; Ferrosulfate; Ferrous sulphate; Iron sulfate (1:1); Combiron; Duretter; Duroferon
Phase 0: 1
Phase 1: 5
Phase 2: 21
Phase 3: 34
Phase 4: 46
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt482 24393 Ferrous Sulfate 3040 HBA2 Homo sapiens (human) Binder
dt483 24393 Ferrous Sulfate 7037 TFRC Homo sapiens (human) Substrate
dt484 24393 Ferrous Sulfate 7036 TFR2 Homo sapiens (human) Substrate
dt485 24393 Ferrous Sulfate 1356 CP Homo sapiens (human) Substrate
dt486 24393 Ferrous Sulfate 57817 HAMP Homo sapiens (human) Substrate
dt487 24393 Ferrous Sulfate 7018 TF Homo sapiens (human) Substrate
dt488 24393 Ferrous Sulfate 9843 HEPH Homo sapiens (human) Substrate
dt489 24393 Ferrous Sulfate 79901 CYBRD1 Homo sapiens (human) 24310424 Substrate
dt490 24393 Ferrous Sulfate 4891 SLC11A2 Homo sapiens (human) Substrate
dt491 24393 Ferrous Sulfate 30061 SLC40A1 Homo sapiens (human) Substrate

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT01991314 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate PHASE4 COMPLETED Queen Mary University of London Ulcerative Colitis|Crohn's Disease DRUG: Ferrous sulphate Details
EUCTR2010-023797-39-GB TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING FERROUS SULPHATE OR COSMOFER: TOLERANCE AND EFFECTS ON HAEMOGLOBIN, DISEASE ACTIVITY, MOOD, QUALITY OF LIFE AND AUTONOMIC NERVOUS SYSTEM ACTIVITY. AN OPEN LABEL PHAS PHASE4 Not Recruiting Barts Health NHS Trust Inflammatory bowel disease . MedDR… Trade Name: Iron sulphate 200mg coated tablets … Details
EUCTR2008-004277-17-GB The effectiveness and tolerability of GlobiFer (haem iron) tablets compared to ferrous sulphate tablets in inflammatory bowel disease: a randomised-controlled trial. - Oral haem to treat anaemia in patients with IBD PHASE2 Not Recruiting GlobiFer International bvba Anaemia in inflammatory bowel disease;Therapeutic… Trade Name: Actavis FERROUS SULPHATE TABLETS BP 2… Details
NCT02086968 Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass PHASE4 COMPLETED American Regent, Inc. Iron Deficiency Anemia Secondary to IBD or Gastri… DRUG: Injectafer|DRUG: Ferrous Sulfate tablets Details
NCT01438372 IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD PHASE2 WITHDRAWN Wayne State University Iron Deficiency Anemia|Inflammatory Bowel Disease DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… Details
NCT05225545 Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis PHASE3 UNKNOWN American University of Beirut Medical Center Anemia, Iron Deficiency|Ulcerative Colitis DRUG: Sucrosomial Iron|DRUG: Oral Iron Details
NCT02774057 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD PHASE4 UNKNOWN American University of Beirut Medical Center Iron Deficiency Anemia|Inflammatory Bowel Disease DRUG: Captafer®|DRUG: Iron Sulfate Details
NCT01017614 Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia PHASE3 COMPLETED Pharmacosmos A/S Inflammatory Bowel Disease DRUG: Monofer|DRUG: Iron Sulphate Details
EUCTR2009-012544-16-GB A phase III, randomized, comparative, open-label study of intravenous iron oligosaccharide (Monofer) administered by infusions or repeated bolus injections in comparison with oral iron sulphate in inflammatory bowel disease subjects with iron deficiency a PHASE3 Not Recruiting Pharmacosmos A/S Inflammatory bowel disease subjects with iron def… Trade Name: MonoFer Product Name: … Details
CTRI/2009/091/000983 A phase III, randomized, comparative, open-label study of intravenous iron oligosaccharide (Monofer administered by infusions or repeated bolus injections in comparison with oral iron sulphate in inflammatory bowel disease subjects with iron deficiency an PHASE3 Not Recruiting Pharmacosmos AS Health Condition 1: null- Iron Deficiency Anemia … Intervention1: Iron oligosaccharide (Monofer: Stu… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Oral Ferric Maltol Does Not Adversely Affect the Intestinal Microbiome of Patie…

PMID: 34209042
Year: 2021
Relationship Type: Treatment Score: 6.5

BACKGROUND AND AIMS: Altering dietary ferrous sulphate (FS) consumption exacerbates a murine model of colitis and alters the intestinal microbiome. W…

View Details